This ICR collects information from
sponsors and applicants who wish to obtain a priority review
designation or breakthrough therapy designation and those who wish
to disseminate promotional materials for a product under
accelerated approval. FDA determines whether an application
qualifies for priority review for every application, however, an
applicant may expressly request priority review. Respondents submit
information for priority review and breakthrough therapy
designation requests, including the proposed indication and a
summary of the information that supports the designation request,
as described in the guidance. Respondents submit promotional
materials for accelerated approval under 21 CFR 314.550, including
promotional labeling as well as advertisements, as described in the
regulation. FDA uses the information submitted in priority review
and breakthrough therapy designation requests to assess whether
drug products meet the criteria for the designations. FDA uses the
information from promotional materials for accelerated approval
products to assess whether the material complies with FDA
requirements
ILa Mizrachi 301 796-7726
ila.mizrachi@fda.hhs.gov
No
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.